The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The impact of pre-existing autoimmune disease on safety & efficacy of CAR-T for non-Hodgkin lymphoma
Charles Gaulin, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a retrospective analysis assessing the impact of pre-existing autoimmune disease (AID) on the safety and efficacy of CAR T-cell therapy for non-Hodgkin lymphoma (NHL). Although patients with AID in this analysis were not found to have poorer outcomes following CAR-T than those without an AID, Dr Gaulin highlights that the most common AID in this analysis was hypothyroidism and that severe AIDs such as rheumatoid arthritis and systemic lupus erythematosus (SLE) were represented by very small sample sizes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
